Title (en)

USE OF A COMPOUND MODULATING AT LEAST ONE RECEIVER SELECTED IN A GROUP COMPRISING AN INTERLEUKIN 8 TYPE B RECEPTOR AND PACAP-1 RECEPTOR FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR ROSACEA TREATMENT

Title (de)

VERWENDUNG EINER VERBINDUNG ZUR MODULIERUNG MINDESTENS EINES EMPFÄNGERS AUSGEWÄHLT AUS EINER GRUPPE AUS EINEM INTERLEUKIN 8 TYP B REZEPTOR UND PACAP-1 REZEPTOR ZUR HERSTELLUNG EINER PHARMAZEUTISCHEN ZUSAMMENSETZUNG ZUR BEHANDLUNG VON ROSACEA

Title (fr)

UTILISATION D'UN COMPOSE MODULATEUR D'AU MOINS UN RECEPTEUR CHOISI PARMI LE RECEPTEUR DE TYPE B DE L'IL 8 ET DE TYPE 1 DE PACAP POUR LA PREPARATION D'UNE COMPOSITION PHARMACEUTIQUE POUR TRAITER LA ROSACEE

Publication

EP 1718285 A2 20061108 (FR)

Application

EP 05729353 A 20050217

Priority

• FR 2005000366 W 20050217
• FR 0401716 A 20040220

Abstract (en)

[origin: FR2866565A1] Compounds (I) that enhance binding of natural ligands to IL-8RB or PAC-1 receptors, other than metronidazole, are used to prepare pharmaceutical compositions for treating rosacea. ACTIVITY : Dermatological. MECHANISM OF ACTION : IL-8RB receptor modulator; PAC-1 receptor modulator. Test details are described but no results for the compounds of the claims are given.

IPC 8 full level

A61K 31/00 (2006.01); A61K 31/40 (2006.01); A61P 17/00 (2006.01)

CPC (source: EP US)

A61K 31/40 (2013.01 - EP US); A61P 17/00 (2017.12 - EP)

Citation (search report)

See references of WO 2005079770A2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)

LV

DOCDB simple family (publication)

FR 2866565 A1 20050826; CA 2553188 A1 20050901; EP 1718285 A2 20061108; US 2008033060 A1 20080207; WO 2005079770 A2 20050901; WO 2005079770 A8 20051027

DOCDB simple family (application)

FR 0401716 A 20040220; CA 2553188 A 20050217; EP 05729353 A 20050217; FR 2005000366 W 20050217; US 58999105 A 20050217